February 19, 2025
FOCUS on New Drug Approvals. Last Friday the FDA granted full approval of Deciphera’s Romvimza™ (Vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) […]
February 14, 2025
FOCUS on New Drug Approvals. Yesterday the FDA approved SpringWorks Therapeutics‘ Mirdametinib (PD-325901) for the treatment of patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas […]
January 13, 2025
Focus on elimination of senescent cancer cells. Researchers at the Netherlands Cancer Institute just reported in PNAS that SLC25A23 (involved in mitochondrial transmembrane transport) is a […]
December 19, 2024
Focus on Drug Approvals. This week the FDA approved Ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer. Ensartinib is a potent and specific […]
November 26, 2024
Focus on Drug Approvals. The FDA has approved Syndax Pharmaceuticals’ Revumenib (SNDX-5613, inhibitor of menin-KMT2A interaction) for relapsed or refractory acute leukemia with lysine methyltransferase 2A […]
November 19, 2024
Focus on Drug Discovery. A biopharmaceutical company called Soligenix is developing the natural product hypericin as a treatment for cutaneous T-cell lymphoma. Hypericin, applied as a […]
August 20, 2024
Drug Approval News: The FDA has approved JNJ’s Rybrevant® (Amivantamab-vmjw plus Lazertinib) as a first line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. Lazertinib […]
July 9, 2024
Focus on Natural Products: Microcystin LR, a cyanobacterial toxin that inhibits protein phosphatase 2A, was recently shown to stimulate tumor-associated macrophages to adopt an anti-tumor M1 […]
February 10, 2023
J Zhang and coworkers at Leiden University Med Ctr have shown that a splice variant of the ubiquitin specific protease, USP19-CY, can enhance the epithelial-mesenchymal transition […]